metadata:
  generated_date: '2025-06-25T21:06:25.434636'
  data_source: ClinicalTrials.gov
  total_trials_analyzed: 127
  note: Parameters estimated from Retinitis Pigmentosa clinical trials
phase_durations_years:
  PHASE1:
    min: 1.0
    median: 2.0
    max: 3.0
    mean: 2.0
    std: 0.5
    count: 0
  PHASE2:
    min: 2.0
    median: 3.0
    max: 4.0
    mean: 3.0
    std: 0.5
    count: 0
  PHASE3:
    min: 3.0
    median: 4.0
    max: 5.0
    mean: 4.0
    std: 0.5
    count: 0
  PHASE1, PHASE2:
    min: 2.0
    median: 3.5
    max: 5.0
    mean: 3.5
    std: 0.75
    count: 0
  PHASE2, PHASE3:
    min: 3.0
    median: 4.5
    max: 6.0
    mean: 4.5
    std: 0.75
    count: 0
phase_success_rates:
  PHASE1:
    success_rate: 0.8620689655172413
    success_count: 25
    total_count: 29
    confidence: measured
  PHASE2:
    success_rate: 0.7837837837837838
    success_count: 29
    total_count: 37
    confidence: measured
  PHASE3:
    success_rate: 0.7142857142857143
    success_count: 10
    total_count: 14
    confidence: measured
regulatory_timelines_years:
  BLA_MAA_submission:
    min: 0.5
    median: 1.0
    max: 1.5
    mean: 1.0
    std: 0.25
    note: Time from Phase 3 completion to regulatory submission
  regulatory_review:
    min: 0.5
    median: 1.0
    max: 2.0
    mean: 1.0
    std: 0.5
    note: FDA/EMA review period
simulation_parameters:
  n_simulations: 10000
  random_seed: 42
  distribution_type: triangular
  note: Use triangular distribution with (min, mode=median, max)
